LIFEVANTAGE CORP Stock Repurchase Program, Authorized Amount
LIFEVANTAGE CORP (LFVN) had Stock Repurchase Program, Authorized Amount of $60.00 million as of 2022-02-17, per its 10-Q filed 2024-05-02.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramAuthorizedAmount1 · last filed 2024-05-02
- 2022-02-17: Stock Repurchase Program, Authorized Amount $60.00M.
- 2020-08-27: Stock Repurchase Program, Authorized Amount $35.00M.
- 2019-02-01: Stock Repurchase Program, Authorized Amount $15.00M.
- 2017-11-27: Stock Repurchase Program, Authorized Amount $5.00M.
| Period end | Stock Repurchase Program, Authorized Amount |
|---|---|
| 2022-02-17 | $60.00M 10-Q · filed 2024-05-02 |
| 2020-08-27 | $35.00M 10-Q · filed 2024-05-02 |
| 2019-02-01 | $15.00M 10-Q · filed 2024-05-02 |
| 2017-11-27 | $5.00M 10-Q · filed 2024-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |